Tag: Catalyst

Automobile Exhaust Catalyst Market Growth and Demand, Product Overview, Company Profiles and Recent Business Development, Forecast to 2020-2026

The MarketWatch News Department was not involved in the creation of this content.

Sep 02, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry”.

Global “Automobile Exhaust Catalyst Market” report business can effectively gain a holistic view of the market and then also benchmark all the companies in the industry. Analysts have studied the data of revenue, production, and manufacturers of each region. Understanding the segments helps in identifying the importance of different factors that aid the market growth. This report represents overall Automobile Exhaust Catalyst market size by analyzing historical data and future prospect. It also provides useful recommendations for new as well as established players of the Automobile Exhaust Catalyst market.

Segments of the Automobile Exhaust Catalyst market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. Market participants can use

Read More

Catalyst Pharmaceuticals Looks Cheap, but Few Catalysts for Massive Upside

Investors often get excited about small-cap biotech and emerging pharmaceutical stocks because the upside can be exponential if their drugs and treatments become a hit. Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) has been one of those companies, but expectations also have been tempered.

Catalyst’s Firdapse is approved as a treatment for Lambert-Eaton myasthenic syndrome in those who are 17 years of age or older. This syndrome is a rare autoimmune neuromuscular disorder, and its U.S. population is estimated to be 1 in 100,000 people. Catalyst just started generating its revenues in 2019, and investors are trying to figure out if there are other drivers after earnings.



a close up of a bottle


© Provided by 24/7 Wall St.


Firdapse’s net revenues of $29.6 million in its second quarter seemed to indicate a slower decline than what had been feared. There also were improvements in the 90-day discontinuation rate.

Loading...

Load Error

One key driver for the August disappointment

Read More